Showing recent highlights
Lifestyle
PubMed · December 31, 2026
This study looked at what happened when overweight college-age women took different amounts of caffeine before doing 40 minutes of moderate-paced treadmill walking — specifically walking at the speed where their bodies burned the most fat. The researchers found that a moderate caffeine dose (roughly 3–5 mg per kilogram of body weight — so about 200–340 mg for a 150-pound person, roughly the amount in 2–3 cups of coffee) taken before that walk increased the amount of fat the body burned during exercise compared to no caffeine, without raising heart rate or blood pressure the way the higher doses did. The evidence is early and was tested in a small group of young women, so it's worth discussing with your doctor before making any changes, especially since caffeine affects everyone differently.
Ask your doctor: Ask the doctor whether drinking caffeine before I exercise might help the patient's body burn more fat during workouts.
What's New
PubMed · December 31, 2026
Researchers found that men with obesity who combined a plant-based supplement called fisetin with a 12-week exercise program — mixing strength training and cardio — showed notable improvements in inflammation and blood sugar control compared to those who only exercised or only took the supplement. Specifically, levels of a natural inflammation-calming molecule in the body called Maresin-1 went up, while markers of inflammation and insulin resistance (a sign the body is struggling to manage blood sugar properly) went down most in the group that did both. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 31, 2026
Researchers found that taking a pasteurized probiotic supplement (called Akkermansia muciniphila) for 3 months showed some promising results for people with prediabetes — a condition where blood sugar is higher than normal but not yet at diabetes levels. In particular, people who naturally had low levels of this beneficial gut bacteria to begin with seemed to benefit the most, showing improvements in how well their body responds to insulin (the hormone that manages blood sugar), as well as reductions in body weight and trunk fat. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 31, 2026
A study found that a probiotic supplement (called LP5282, made from heat-treated bacteria) helped overweight adults lose weight and body fat — but only in people who started out with less variety of bacteria in their gut. Researchers found that people with a less diverse gut microbiome (the community of bacteria living in the digestive tract) saw meaningful reductions in body weight and a hormone called leptin, which is linked to appetite and fat storage, while people with a more diverse gut microbiome didn't see the same benefits. This suggests that the makeup of a person's gut bacteria might play a role in how well certain weight-related supplements work for them. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 30, 2026
A study found that people who took a supplement called Forcslim for 12 weeks lost about 1.93 kg (roughly 4 pounds) more than those who took a placebo (a dummy pill with no active ingredient), and also saw their waist size shrink by about 1.83 cm. Researchers also found improvements in blood fat levels — specifically, a drop in triglycerides (a type of fat in the blood linked to heart health) and a rise in HDL, often called 'good' cholesterol — with no worrying side effects reported. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 30, 2026
Researchers found that overweight and obese women who followed a 4-week exercise program saw reductions in chest and abdominal measurements, along with improvements in reproductive hormones linked to fertility. Adding cinnamon supplements to the exercise routine made a small additional difference in chest size, but did not produce significantly greater changes in belly size or hormone levels compared to exercise alone. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · December 1, 2026
This study compared two weight-loss medications — tirzepatide (brand name Mounjaro or Zepbound) and semaglutide (brand name Wegovy or Ozempic) — in people with obesity or excess weight. Researchers found that tirzepatide not only helped people lose more weight and reduced the risk of serious health problems like serious heart problems like heart attacks or strokes, but it was also estimated to cost less overall when factoring in healthcare and broader life costs. This appears to be a new finding about how these two medications compare, rather than a safety update or guideline change.
Ask your doctor: Ask the doctor whether tirzepatide might work better for the patient's weight loss than semaglutide, since studies show it helped people lose more weight.
What's New
PubMed (Open Access Guidelines) · December 1, 2026
Researchers found that whole-body vibration training — a type of exercise where people stand or move on a platform that vibrates — helped lower resting blood pressure in adults. The effect was especially noticeable in people who already had higher blood pressure or who were overweight, with their top blood pressure number dropping by more than 11 points on average in those groups. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 1, 2026
A study found that people with type 2 diabetes and high blood pressure who lost weight through a dietary program — about 25 pounds on average over 12 months — were able to cut back on their high blood pressure medications, yet their blood pressure stayed just as well controlled as before. In fact, their heart rate and certain measures of blood pressure fluctuation during the night also improved. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 1, 2026
Researchers found that people with psoriasis who are obese may not respond as well to certain biologic medications — powerful treatments that target the immune system to clear skin — compared to people who are not obese. The difference was most noticeable with two specific types of biologics (those targeting proteins called IL-17 and IL-12/23), while other types did not show the same pattern, though the evidence is still limited. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · December 1, 2026
Researchers found that a compound called sodium pentaborate pentahydrate — a form of boron, a naturally occurring mineral — helped people with obesity or overweight lose a modest amount of body weight over 12 weeks, with the highest dose (1,000 mg) showing the greatest effect compared to a sugar pill. No major safety concerns were flagged during the trial period, which is an encouraging early sign. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · September 2, 2026
Even after someone loses weight, their immune cells — the cells that help the body fight illness and inflammation — may carry a kind of "memory" of having been obese for up to 5 to 10 years. This could help explain why some health risks linked to obesity don't fully disappear just because the number on the scale goes down. For people managing obesity, this suggests that the body's recovery may be a longer and more complex process than weight loss alone.
What's New
PubMed · September 2, 2026
A study found that people with prediabetes who used an AI-powered smartphone app more often were more likely to lose enough weight and increase their physical activity to lower their risk of developing diabetes. Interestingly, older adults and those with a lower starting body weight tended to use the app most consistently, which researchers found surprising since younger people are often assumed to be more comfortable with technology. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that limiting meals to a 10-hour window each day — for example, eating only between 9am and 7pm — did not produce noticeably different results in appetite or inflammation compared to people who ate over a longer 16-hour window, as long as both groups consumed the same number of calories. Both groups lost a similar amount of weight and reported feeling less hungry and more in control of their eating habits by the end of the 12 weeks. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that combining a diabetes medication like Ozempic or Victoza with structured exercise led to greater reductions in body weight, body fat, and waist size than either approach alone in adults with overweight or obesity. The combination also appeared to improve insulin resistance — meaning the body got better at responding to insulin and managing blood sugar — more than a placebo did. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · September 1, 2026
Researchers found that tirzepatide (brand name Mounjaro), a diabetes medication like Ozempic or Victoza, was linked to fewer serious heart problems like heart attacks or strokes in people with type 2 diabetes or obesity. The analysis looked at 22 studies involving more than 29,000 people and also found that those taking tirzepatide were less likely to die from any cause compared to those who weren't taking it. This appears to be a new finding about tirzepatide's heart-related benefits, and researchers noted that higher doses were linked to even greater reductions in serious heart problems.
Medications
PubMed · September 1, 2026
Researchers found that a synthetic version of semaglutide — the active ingredient in Wegovy, a diabetes and weight-loss medication like Ozempic — worked just as well as the brand-name Wegovy for helping people with obesity lose weight. In the study, people in both groups lost roughly 14% of their body weight over 24 weeks, and more than 96% of participants lost at least 5% of their body weight. This appears to be a new option being evaluated as an alternative to Wegovy, with similar results for weight loss and blood sugar control.
What's New
PubMed · September 1, 2026
Researchers found that among children and teens with obesity, different diabetes medications like Ozempic or Victoza had different effects on weight and blood sugar control — for example, one version called semaglutide was linked to the largest drops in body weight (about 18 kg on average), while another called dulaglutide showed the strongest improvement in blood sugar level (A1C). This matters because obesity in young people raises the risk of serious health problems later in life, and knowing which medications may work best could help doctors have better-informed conversations with families. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · September 1, 2026
A study found that tirzepatide — sold under the brand name Zepbound for obesity and Mounjaro for diabetes — helped people with obesity lose meaningful amounts of weight and improve their overall health markers, including blood sugar level (A1C). Researchers looked at whether people who lost at least 5% of their body weight within the first 8 weeks of treatment (called 'early responders') did better overall, and found that they did see greater improvements compared to those who lost less weight early on. This is a new finding about how early weight loss on tirzepatide may signal better long-term results, which is something people might find helpful to discuss with their doctor.
What's New
PubMed · September 1, 2026
Researchers found that a diabetes medication like Ozempic or Victoza helped protect against serious heart problems like heart attacks or strokes equally well in people with type 2 diabetes, regardless of whether they also had reduced kidney function — meaning the kidneys' ability to filter blood was lower than normal. What's especially interesting is that people with reduced kidney function appeared to get a somewhat larger real-world benefit, because their overall heart risk was already higher to begin with. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that survodutide — a newer medication that works similarly to a diabetes medication like Ozempic or Victoza but also activates a second biological pathway — helped improve how well the body responds to insulin (meaning the body needed less insulin to manage blood sugar) and improved blood sugar control in people with type 2 diabetes. Some of these improvements appeared to go beyond just the weight loss the medication caused, suggesting the drug may have direct benefits on how the body handles blood sugar. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that when people with overweight or obesity lose weight, the method they use affects how much muscle and lean body tissue they lose along the way — not just fat. Diet combined with exercise preserved the most lean tissue, with only about 8% of the weight lost coming from muscle and lean mass, while medications like a diabetes medication like Ozempic or Victoza and weight-loss surgery led to losing roughly a third of their total weight from lean tissue rather than fat. This matters because keeping muscle and lean tissue during weight loss is important for strength, metabolism, and long-term health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a non-surgical procedure called endoscopic sleeve gastroplasty — where a flexible tube is used through the mouth to stitch the stomach into a smaller shape, without any outside incisions — helped people with obesity lose a meaningful amount of weight and mostly keep it off for several years. In a large review of nearly 9,000 patients, weight loss peaked around one year and then dipped only slightly by year three, and more than six in ten people with type 2 diabetes saw their condition go into remission, meaning their blood sugar improved significantly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a diabetes medication like Ozempic or Victoza (called semaglutide) may help people with a type of heart failure called HFpEF — where the heart pumps normally but is too stiff to fill properly — especially when obesity is also involved. Across six studies with over 4,000 patients, those taking semaglutide felt better, had lower levels of a key marker in the blood that signals heart strain, and were less likely to end up in the hospital for heart failure. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether semaglutide might help the patient's heart failure symptoms and exercise ability, since research shows it may be beneficial for people who have heart failure with preserved ejection fraction and obesity.
What's New
PubMed · September 1, 2026
Researchers found that for people with chronic kidney disease (CKD — a condition where the kidneys gradually lose their ability to filter waste from the blood) who also carry extra weight, certain weight-loss approaches may help protect the kidneys. Bariatric surgery (a procedure that reduces the size of the stomach to help people lose significant weight) was linked to a meaningful improvement in how well the kidneys filter blood, and medications similar to a diabetes medication like Ozempic or Victoza were associated with a 41% drop in a key protein in the urine — a sign that the kidneys may be under less strain. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a structured group therapy program focused on managing emotions helped people with a form of multiple sclerosis (MS) — a disease that affects the brain and nervous system — who were also living with excess weight. Participants who went through the 14-session program showed improvements in anxiety, depression, emotional eating, and even some physical health measures like body weight, compared to those who received standard medical care alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people who stopped taking a diabetes medication like Ozempic or Victoza (semaglutide) or a similar drug called tirzepatide regained weight fairly quickly after stopping — about half of the weight they had lost came back within roughly seven and a half months, and most people returned close to their starting weight within about fifteen months. The study also found that people who lost more weight during treatment tended to regain it faster afterward, possibly because the body works harder to return to its previous weight. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers are studying two types of weight-loss surgery to see which one works better for people with severe obesity — a newer procedure called single-anastomosis sleeve ileal bypass and the more commonly used sleeve gastrectomy, which reduces the size of the stomach. The study is looking at how much weight people lose, as well as other health factors like digestive problems, bone health, and quality of life, tracked over five years. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people who had already lost weight and then used a continuous glucose monitor — a small wearable device that tracks blood sugar levels throughout the day — alongside personalized nutrition coaching kept losing weight over 24 weeks, while those who only received the coaching sessions slightly regained weight. This suggests that seeing real-time blood sugar data may help people make better food and activity choices, which could be especially meaningful for people with obesity who struggle to keep weight off after losing it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that TERN-601, an experimental pill version of a diabetes medication like Ozempic or Victoza, helped people with obesity lose weight over 12 weeks — with higher doses leading to more weight loss. However, some participants showed signs of possible liver damage during the study, which was serious enough that the drug's development was stopped entirely. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.